Detalhe da pesquisa
1.
Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma.
Int J Clin Oncol
; 29(6): 764-770, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38555323
2.
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study).
Br J Cancer
; 129(6): 1032-1039, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37532830
3.
Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
Oncologist
; 28(11): e1108-e1113, 2023 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37284901
4.
Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study.
Int J Clin Oncol
; 28(6): 756-763, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36943545
5.
Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center.
Int J Clin Oncol
; 28(5): 644-653, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36899286
6.
[Discrepancy in Gastric Cancer Chemotherapy between the Asia and West].
Gan To Kagaku Ryoho
; 50(1): 23-29, 2023 Jan.
Artigo
em Japonês
| MEDLINE | ID: mdl-36759981
7.
The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma.
Esophagus
; 20(3): 524-532, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36595124
8.
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
Gut
; 71(7): 1277-1288, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34433583
9.
Cholangitis with Sphingobacterium multivorum and Acinetobacter junii bacteremia in a patient with gastric cancer: A case report.
J Infect Chemother
; 28(10): 1419-1423, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35718261
10.
An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study.
Future Oncol
; 17(19): 2431-2438, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33764163
11.
REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer.
Future Oncol
; 17(8): 869-875, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32954810
12.
A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study.
Int J Clin Oncol
; 26(4): 701-707, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33386556
13.
Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer.
Oncologist
; 25(11): e1614-e1620, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32490554
14.
A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer.
Oncologist
; 24(2): 159-e66, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30305415
15.
Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
Gastric Cancer
; 21(6): 1050-1057, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658055
16.
Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody.
Oncology
; 92(4): 205-212, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28142137
17.
Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.
Oncology
; 93(5): 329-335, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28866662
18.
Immunotherapy for gastroenterological cancer.
Nihon Rinsho
; 75(2): 229-233, 2017 02.
Artigo
em Japonês
| MEDLINE | ID: mdl-30562857
19.
A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer.
Jpn J Clin Oncol
; 46(3): 228-33, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26759349
20.
Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
Int J Clin Oncol
; 21(5): 890-898, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26980212